Why 2018 is a make-or-break year for pharma By: MarketWatch December 19, 2017 at 17:33 PM EST Many profitable products are aging, and some companies don’t have many new candidates to replace them. Read More >> Related Stocks: Biomarin Pharmaceuticals Celgene Corp Clovis Oncology Inc Gilead Sciences Incyte Corp Johnson & Johnson Neurocrine Bioscienc Novo Nordisk A/S ADR S&P Biotech SPDR S&P Pharmaceuticals SPDR Sage Therapeutic Com Sarepta Therapeutics Tesaro Inc